Industry Briefs

Premium

MDS Q1 Revs Down 13 Percent, Mass Spec Unit Down 27 Percent; Renews Shareholders Rights Plan

MDS reported last week that its first-quarter revenues fell 13 percent year over year, with its MDS Analytical Technologies segment, which houses its mass spectrometry business, posting a 27 percent decline in revenues.

The firm brought in total revenues of $257 million for the three-month period ended Jan. 31. It said that excluding the impact of foreign exchange, acquisitions, and divestitures, revenues were down 1 percent compared to the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.